Pacific Biosciences of California Inc (NASDAQ: PACB) kicked off on Monday, up 2.87% from the previous trading day, before settling in for the closing price of $2.44. Over the past 52 weeks, PACB has traded in a range of $1.16-$10.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.48%. While this was happening, its average annual earnings per share was recorded 7.73%. With a float of $259.36 million, this company’s outstanding shares have now reached $267.74 million.
Let’s determine the extent of company efficiency that accounts for 796 employees. In terms of profitability, gross margin is 19.6%, operating margin of -166.74%, and the pretax margin is -218.04%.
Pacific Biosciences of California Inc (PACB) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 4.83%, while institutional ownership is 83.73%. The most recent insider transaction that took place on Sep 30 ’24, was worth 34,065. In this transaction an insider of this company sold 19,782 shares at a rate of $1.72, taking the stock ownership to the 695,654 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Officer proposed sale 19,782 for $1.72, making the entire transaction worth $34,061.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.26 earnings per share (EPS), higher than consensus estimate (set at -0.33) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Take a look at Pacific Biosciences of California Inc’s (PACB) current performance indicators. Last quarter, stock had a quick ratio of 7.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.50, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Looking closely at Pacific Biosciences of California Inc (NASDAQ: PACB), its last 5-days average volume was 10.19 million, which is a jump from its year-to-date volume of 9.36 million. As of the previous 9 days, the stock’s Stochastic %D was 84.30%. Additionally, its Average True Range was 0.19.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 95.07%, which indicates a significant increase from 92.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.83% in the past 14 days, which was lower than the 118.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.77, while its 200-day Moving Average is $2.69. However, in the short run, Pacific Biosciences of California Inc’s stock first resistance to watch stands at $2.61. Second resistance stands at $2.72. The third major resistance level sits at $2.85. If the price goes on to break the first support level at $2.37, it is likely to go to the next support level at $2.24. Should the price break the second support level, the third support level stands at $2.13.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
The company with the Market Capitalisation of 769.16 million has total of 272,529K Shares Outstanding. Its annual sales at the moment are 200,520 K in contrast with the sum of -306,740 K annual income. Company’s last quarter sales were recorded 36,010 K and last quarter income was -173,320 K.
